Nuclear Medicine and Biology
Volume 37, Issue 8 , Pages 869-871 , November 2010

Rat pancreas uptake of [11C]dihydrotetrabenazine stereoisomers

Received 3 May 2010 ,Revised 21 May 2010 ,Accepted 1 June 2010.

References 

  1. Kilbourn MR. PET radioligands for vesicular neurotransmitter transporters. Med Chem Res. 1994;5:113–126
  2. Inabnet WB, Milone L, Harris P, Durak E, Freeby MJ, Ahmed L, et al. The utility of [11C]dihydrotetrabenazine positron emission tomography scanning in assessing beta-cell performance after sleeve gastrectomy and duodenal–jejunal bypass. Surgery. 2010;147:303–309
  3. Kung HF, Lieberman BP, Zhuang ZP, Oya S, Kung MP, Choi SR, et al. In vivo imaging of vesicular monoamine transporter 2 in pancreas using an (18)F epoxide derivative of tetrabenazine. Nucl Med Biol. 2008;35:825–837
  4. Freeby M, Goland R, Ichise M, Maffei A, Leibel R, Harris P. VMAT2 quantitation by PET as a biomarker for beta-cell mass in health and disease. Diabetes Obes Metab. 2008;(Suppl 4):98–108
  5. Kung MP, Hou C, Lieberman BP, Oya S, Ponde DE, Blankemeyer E, et al. In vivo imaging of beta-cell mass in rats using 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus. J Nucl Med. 2008;49:1171–1176
  6. Saudek F, Brogren CH, Manohar S. Imaging the beta-cell mass: why and how. Rev Diabet Stud. 2008;5:6–12
  7. Harris PE, Ferrara C, Barba P, Polito T, Freeby M, Maffei A. VMAT2 gene expression and function as it applies to imaging beta-cell mass. J Mol Med. 2008;86:5–16
  8. Simpson NR, Souza F, Witkowski P, Maffei A, Raffo A, Herron A, et al. Visualizing pancreatic beta-cell mass with [11C]DTBZ. Nucl Med Biol. 2006;33:855–864
  9. Souza F, Simpson N, Raffo A, Saxena C, Maffei A, Hardy M, et al. Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model. J Clin Invest. 2006;116:1506–1513
  10. Eriksson O, Jahan M, Johnstrom P, Korsgren O, Sundin A, Halldin C, et al. In vivo and in vitro characterization of [18F]-FE-(+)-DTBZ as a tracer for beta-cell mass. Nucl Med Biol. 2010;37:357–363
  11. Tsao H-H, Lin K-J, Juang JH, Skrovonsky DM, Yen T-C, Wey S-P, et al. Binding characteristics of 9-fluoropropyl-(+)-dihydrotetrabenazine (AV-133) to the vesicular monoamine transporter type 2 in rats. Nucl Med Biol. 2010;37:413–419
  12. Kilbourn MR, Lee L, Vander Borght T, Jewett D, Frey K. Binding of α-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. Eur J Pharmacol. 1995;278:249–252
  13. Koeppe RA, Frey KA, Kuhl DE, Kilbourn MR. Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine. J Cerebral Blood Flow Metab. 1999;19:1376–1384
  14. Mehvar R, Jamali F. Concentration–effect relationships of tetrabenazine and dihydrotetrabenazine in the rat. J Pharm Sci. 1987;76:461–465
  15. Mehvar R, Jamali F, Watson MW, Skelton D. Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies. Drug Metab Dispos. 1987;15:250–255

PII: S0969-8051(10)00305-7

doi: 10.1016/j.nucmedbio.2010.06.001

Nuclear Medicine and Biology
Volume 37, Issue 8 , Pages 869-871 , November 2010

Article Tools